生命科学资讯

FDA suspends Regenxbio gene therapy trials after patient developed brain tumor

HHS seeks to protect drugmakers from anti-kickback laws ahead of TrumpRx launch

Eikon seeks $273M IPO with pipeline led by Chinese cancer drugs

Included Health launches alternative health plan

Hengrui blazes trail as Chinese drugmakers aspire to go multinational

Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations

Hospitals could earn more for buying US-made drugs, CMS proposes

Cardiff execs depart as company drops mixed Phase 2 data

UnitedHealth projects lower revenue in 2026 as it resets its business

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma

AstraZeneca ends work on cardio drug; Lisata and Qilu terminate deal

Virtual women’s health company Wisp buys TBD Health

Boehringer Ingelheim gets an IBD bispecific from Shanghai-based Simcere

UK-US biotech investor Epidarex raises $145M for fourth fund

IRA drug pricing petitions pile up at the Supreme Court

Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump scheme

Catalent plans to close Belgium cell therapy site

Sarepta touts three-year Duchenne gene therapy data after patient deaths